Green Circle Decarbonize Technology Limited Transitions to OTC Trading Platform

NYSE American suspended trading in Green Circle Decarbonize Technology Limited’s Class A ordinary shares on November 3, 2026, after determining the shares were no longer suitable for listing because of their low selling price; delisting proceedings have begun. The company intends to request a review within the applicable seven-calendar-day period and anticipates trading on OTC Pink, while stating that operations and SEC reporting obligations will continue. The company warns that OTC trading could involve reduced liquidity and further share-price declines.

Analysis

This is primarily a market-structure and financing-risk event, not evidence by itself of deterioration in Green Circle’s operating business. The immediate suspension removes price discovery; a move to OTC, if it occurs, can widen spreads, reduce institutional and broker access, and make any equity-funded strategic transaction harder to execute or less attractive to counterparties. Those effects can reinforce one another even if the underlying business is unchanged. The company’s stated intention to appeal is not a reinstatement outcome, and its comments about continued reporting and strategic opportunities are not evidence of transaction progress.

Over the next several days, the key binary is whether the appeal is timely accepted and whether NYSE American changes its determination. Over 1–3 months, verify where and when trading resumes, actual OTC liquidity, and subsequent SEC filings for concrete transaction milestones. Over 6–18 months, persistent trading and financing constraints could become more consequential than the original listing issue if the company needs capital or stock consideration. The main contrarian point is that delisting mechanics alone do not establish impaired operations; however, treating the event as merely technical underweights the potential liquidity and financing feedback loop. No comparable-company or supplier read-through is supported by the supplied information.

Key Decisions for Investors

• Avoid initiating a directional position while trading is suspended and OTC venue, broker access, and executable liquidity remain unverified; shorting is also unattractive without confirmed borrow and liquidity.
• For existing holders, treat any OTC reopening as a high-slippage event: use limit orders only if trading is available, and reassess position sizing against the possibility of materially reduced exit liquidity.
• Set an event watch through the appeal window: verify the Panel review request and any NYSE American decision, then confirm the actual OTC trading start and market tier rather than relying on the company’s expectation.
• Falsifiers and escalation triggers: a reversal of the delisting determination or demonstrably stable OTC liquidity would weaken the market-access thesis; failure to regain listing, prolonged trading disruption, deteriorating SEC-reporting compliance, or no verifiable progress on a strategic transaction would strengthen it.